Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
NCT01206296
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
9
Enrollment
OTHER
Sponsor class
Stopped
Study suspended
Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG:
Intraperitoneal Gemcitabine
Sponsor
Medstar Health Research Institute